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Summary
BRCA1 and BRCA2 are often mutated in familial breast and
ovarian cancer. Both tumor suppressors play key roles in
the DNA-damage response [1, 2]. However, it remains
unclear whether these two tumor suppressor function
together in the same DNA-damage response pathway.
Here, we show that BRCA1 associates with BRCA2 through
PALB2/FANCN, a major binding partner of BRCA2 [3]. The
interaction between BRCA1 and BRCA2 is abrogated in
PALB2-deficient Fanconi anemia cells and in the cells
depleted of PALB2 by small interfering RNA. Moreover, we
show that BRCA1 promotes the concentration of PALB2
and BRCA2 at DNA-damage sites and the interaction
betweenBRCA1 andPALB2 is important for the homologous
recombination repair. Taken together, our results indicate
that BRCA1 is an upstream regulator of BRCA2 in the DNA-
damage response, and PALB2 is the linker between BRCA1
and BRCA2.
Results and Discussion
PALB2 Interacts with BRCA1
Recently, by protein affinity purification, PALB2 has been
identified as a functional partner of BRCA2 [3]. Importantly,
germline mutations of PALB2 have been found in breast
cancer families, indicating that PALB2, like BRCA1 and
BRCA2, is a tumor suppressor for familial breast cancers [4–6].
In addition, BRCA2 is also the Fanconi anemia D1 protein
(FANCD1), given that the D1 subtype of FA (FA-D1) has been
attributed to biallelic germline mutations in BRCA2 [7]. Inter-
estingly, like BRCA2, PALB2 is also a FA protein, given that
biallelic germline mutations in PALB2 have been identified in
the N subtype of FA (FA-N) [8, 9].
To identify additional PALB2 binding proteins, we used two
different protein affinity purification approaches to search for
PALB2-associated proteins. In one approach, we purified
Flag-HA-tagged PALB2 from HeLa S3 cells. In the purified
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3These authors contribute equally to this workcomplex, we observed two major components with molecular
weights higher than PALB2 (Figure 1A). Mass spectrometry
analysis demonstrated that the upper band represented
BRCA2, a known PALB2 binding partner [3], and the lower
band, to our surprise, was BRCA1. Alternatively, we purified
S-SPB-tagged PALB2 protein complex from 293T cells and
also identified BRCA1 and BRCA2 as PALB2-associated
proteins (data not shown). To confirm that PALB2 interacts
with BRCA1 under the physiological condition, we performed
reciprocal immunoprecipitation (IP) of the endogenous
proteins and found that they indeed co-IPed with each other
(Figure 1B). Because both PALB2 and BRCA1 participate in
the DNA-damage response, we tested whether DNA double-
strand breaks influence the interaction between these two
proteins. As shown in Figure 1C, the association between
PALB2 and BRCA1 did not change after ionizing radiation
(IR), indicating that, like the interaction between PALB2 and
BRCA2, the interaction between PALB2 and BRCA1 is DNA-
damage independent and occurs constitutively.
BRCA1 Associates with BRCA2 through PALB2
BRCA1 and BRCA2 have been shown to coexist in an endog-
enous protein complex [10, 11]. Because PALB2 associated
with both BRCA1 and BRCA2, we wondered whether PALB2
is the linker between BRCA1 and BRCA2 in the same complex.
To test this possibility, we used siRNA to knock down PALB2
and examined the association between BRCA1 and BRCA2.
As shown in Figure 1E, when cells were treated with PALB2
siRNAs, but not a control siRNA, the association between
BRCA1 and BRCA2 was abolished. The PALB2 siRNAs were
specific, given that they downregulated only PALB2 but
neither BRCA1 nor BRCA2 (Figure 1D). Moreover, in the
PALB2-null EUFA1341 (FA-N) cells, BRCA2 failed to co-IP
with BRCA1, whereas reconstitution of EUFA1341 cells with
wild-type PALB2 restored the association between BRCA1
and BRCA2 (Figure 1F). These results suggest that PALB2
mediates the interaction between BRCA1 and BRCA2. To
further study the BRCA1/PALB2/BRCA2 complex, we have
used different lysis buffer to elute chromatin-bound proteins
and examined the BRCA1/PALB2/BRCA2 complex in different
cell lysate fractions. Interestingly, the complex was only
detected after cells were lyzed with high-salt lysis buffer but
not low-salt lysis buffer, indicating that this complex may
tightly associate with the chromatin (Figure S1 available
online). It is consistent with not only our previous finding that
PALB2 is a chromatin-associated protein [3] but also results
from other groups that BRCA1/BRCA2 complex can be eluted
and detected in the nuclear extracts with high-salt buffer [11].
BRCA1 Is Required for Targeting PALB2
and BRCA2 to DNA-Damage Sites
It has been shown that PALB2 colocalizes with both BRCA1
and BRCA2 at DNA-damage sites [3]. Here, we also confirmed
that the three proteins colocalize together at nuclear foci after
DNA double-strand breaks (Figure S2). Interestingly, PALB2 is
required for the DNA-damage-induced focus formation of
BRCA2, but not BRCA1 [3]. This led us to hypothesize that
BRCA1 may be an upstream regulator of PALB2 and BRCA2.
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Figure 1. PALB2 Mediates the Interaction
between BRCA1 and BRCA2
(A) Silver staining of affinity-purified PALB2
complexes. The nuclear extracts prepared from
naive HeLa S3 cells or cells stably expressing
PALB2-FLAG-HA were subjected to two rounds
of affinity purification. Final elutes were resolved
by SDS-PAGE and stained with silver. The
protein bands were analyzed by mass spectrom-
etry. Arrows indicate protein bands correspond-
ing to BRCA1, BRCA2, and PALB2.
(B) PALB2 interacts with BRCA1. 293T cell
lysates were analyzed by immunoprecipitation
(IP) and western blotting with PALB2 or BRCA1
antibodies respectively. Whole-cell lysates were
blotted and shown as the input. An irrelevant
IgG was used as the IP control.
(C) The interaction between BRCA1 and PALB2 is
DNA-damage independent. 293T cells were
treated with 0 or 10 Gy IR. Extracts prepared
from mock-treated or irradiated 293T cells were
IPed with antibodies against PALB2 and
BRCA1. The precipitates were separated by
SDS-PAGE and immunoblotted with the indi-
cated antibodies. A blot with anti-b-actin anti-
body was used as the protein loading control.
(D) PALB2 siRNAs specifically downregulate
PALB2. HeLa cells were treated with control or
PALB2 siRNA. Cell lysates were examined by
indicated antibodies.
(E) Downregulation of PALB2 abrogates the
association between BRCA1 and BRCA2. HeLa
cells were treated with control or PALB2 siRNAs.
Cell lysates were analyzed by immunoprecipi-
taion and western blotting with indicated anti-
bodies. The amount of b-actin was used as the
protein loading control.
(F) Loss of BRCA1-BRCA2 interaction in PALB2-
deficent Fanconi anemia cells. Whole-cell lysates
of U2OS, FEN5280 (PALB2 wt), EUFA1341
(PALB2-deficent, FA-N), and the reconstituted
EUFA1341-PALB2 cells were analyzed with
indicated antibodies.To test this hypothesis, we examined the focus formation of
PALB2 and BRCA2 in HCC1937 cells, which express a trun-
cated BRCA1 protein that does not have a C-terminal BRCT
domain and that is unable to relocate to DNA-damage sites
[12, 13]. After IR, gH2AX, a surrogate marker of DNA double-
strand breaks, formed foci efficiently in HCC1937 cells.
However, the focus formation of PALB2 and BRCA2 was
significantly impaired in these cells (Figure 2A). In contrast, in
HCC1937 cells reconstituted with the wild-type BRCA1, both
PALB2 and BRCA2 clearly accumulated at DNA-damage sites
marked by gH2AX (Figure 2A), suggesting that BRCA1
promotes the relocation of PALB2 and BRCA2 to DNA-
damage sites. We also treated U2OS cells with BRCA1 siRNAs,
which specifically downregulated BRCA1 but neither PALB2
nor BRCA2 (Figure 2B). Again, in the BRCA1-knockdown cells,
the focus formation of PALB2 and BRCA2 was significantly
impaired (Figure 2C). Taken together, these results demon-
strate that BRCA1 is an upstream regulator of PALB2 and
BRCA2 in the DNA-damage response and is important for
targeting PALB2 and BRCA2 to DNA-damage sites.
Coiled-Coil Domains in BRCA1 and PALB2Directly Interact
with Each Other
It is known that the C-terminal WD40 repeats of PALB2 inter-
acts with the N-terminus of BRCA2 [3, 8]. To map theinteraction domains between BRCA1 and PALB2, we gener-
ated nine internal deletion mutants of BRCA1 and tested their
abilities to interact with PALB2 (Figure 3A). As shown in
Figure 3B, among these mutants only the BD5 mutant failed
to interact with PALB2. To map the BRCA1-interacting region
in PALB2, we generated 13 internal deletion mutants of PALB2
(Figure 4A). Co-IP experiments showed that only the P1
mutant failed to associate with BRCA1 (Figure 4A). This
mutant deletes the N-terminal amino acid 6–90 of PALB2,
which contains an evolutionary conserved coiled-coil motif
(Figure S3A). Interestingly, the region deleted in the BRCA1
BD5 mutant also contains a conserved coiled-coil domain
(Figure S3A), suggesting that the coiled-coil motifs in
BRCA1 and PALB2 may interact with each other to form a
heterodimer.
Next, BRCA1 and PALB2 mutants each deleted of its coiled-
coil motif were generated and tested for their abilities to bind
endogenous PALB2 or BRCA1, respectively. As expected,
both deletion mutants failed to bind (Figure S3B). Moreover,
we also deleted certain conserved residues (‘‘EEK’’ in PALB2
and ‘‘KLQQE’’ in BRCA1) to abolish the coiled-coil motifs.
Again, these small deletion mutants could no longer interact
with wild-type BRCA1 or PALB2, further supporting the notion
that the coiled-coil motifs of BRCA1 and PALB2 mediate this
protein-protein interaction (Figure S3B). To further examine
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Figure 2. BRCA1 Impairs Focus Formation of PALB2 and BRCA2 at DNA-Damage Sites
(A) The DNA-damage-induced focus formation of PALB2 and BRCA2 was impaired in BRCA1-deficient cells. HCC1937 and HCC1937-BRCA1 cells were
treated with 0 or 10 Gy of IR. Cells were stained with indicated antibodies. The percentage of foci positive cells was summarized.
(B) BRCA1 siRNA specifically downregulates BRCA1. U2OS cells were treated with control siRNA or two different BRCA1 siRNA for 48 hr and the whole-cell
lysates were analyzed by western blotting.
(C) Downregulation of BRCA1 impairs the IR-induced focus formation of PALB2 and BRCA2. U2OS cells were treated with the same siRNAs as mentioned
above for 45 hr and then treated with 10 Gy of IR. Cells were fixed 6 hr after IR and costained with indicated antibodies. The results shown were from BRCA1
siRNA #1. BRCA1 siRNA #2 produced similar effects (not shown).whether these two coiled-coil domains interact directly with
each other, we generated and purified the recombinant GST-
tagged coiled-coil domain of PALB2 and His-tagged coiled-
coil domain of BRCA1. As shown in Figure S3C, the two
domains interacted with each other in an in vitro pull-downassay, indicating that they are able to bind to each other
directly. Again, deletions of the conserved residues abrogated
the binding, consistent with the IP results shown above. These
results demonstrate that BRCA1 and PALB2 form a complex
via a direct interaction between their coiled-coil motifs.
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and ATR, and several individual phosphorylation events of
BRCA1 have been reported to participate in BRCA1-depen-
dent cell-cycle checkpoint activation [14, 15]. Some of the
phosphorylation sites in BRCA1 (Ser1387, Ser1423, and
Ser1524 [16–19]) are located within or very close to its
coiled-coil motif. To examine whether these DNA-damage-
induced BRCA1 phosphorylation events affect its interaction
with PALB2, we mutated Ser1387, Ser1423, and Ser1524
each to an alanine. However, all three mutants were still able
to associate with the wild-type PALB2 (Figure S3B), indicating
that DNA-damage-induced single BRCA1 phosphorylation
does not regulate BRCA1 and PALB2 interaction.
The BD5 mutant of BRCA1 that abolished the interaction
with PALB2 could not associate with BRCA2 (Figure S4A), in
keeping with the notion that PALB2 is a linker between
BRCA1 and BRCA2. Because the BD5 mutant contains the
BRCT domain that targets BRCA1 to DNA-damage sites, it still
relocated to DNA-damage sites after IR (Figure 3C). However,
unlike the wild-type BRCA1, this mutant failed to promote
PALB2 and BRCA2 localization to postdamage nuclear foci
(Figure 3C). In the case of PALB2, the P1 mutant that could
not interact with BRCA1 also failed to accumulate to DNA-
damage sites after IR treatment (Figure 4B), although it was
still able to bind BRCA2 (Figure S4B). These results further
support the notion that the association with BRCA1 is critical
for the relocation of PALB2 to the sites of DNA damage.
BRCA1 and PALB2 Interaction Is Important
for BRCA2-Mediated DNA-Damage Repair
It has been shown that BRCA1, BRCA2, and PALB2 all partic-
ipate in homologous recombination (HR) repair after DNA
Figure 3. The Coiled-Coil Domain of BRCA1
Interacts with PALB2 and Targets PALB2 and
BRCA2 to DNA-Damage Sites
(A) The schematic diagrams of BRCA1 and its
mutants.
(B) The coiled-coil domain of BRCA1 interacts
with PALB2. Wild-type BRCA1 and its internal
deletion mutants were expressed in 293T cells.
The interaction between PALB2 and the BRCA1
species were examined with indicated anti-
bodies.
(C) The coiled-coil domain of BRCA1 is important
for targeting PALB2 and BRCA2 to DNA-damage
sites. Wild-type BRCA1 or the BD5 mutant was
expressed in HCC1937 cells. Cells were treated
with 10 Gy of IR and then stained with indicated
antibodies.
double-strand breaks [3, 20, 21].
Especially, BRCA2 plays an essential
role in HR by facilitating RAD51 to poly-
merize along the single-stranded DNA
generated, which invades the template
duplex DNA and pairs with a homolo-
gous region to initiate HR [22]. Thus,
we examined whether the interaction
between BRCA1 and PALB2 would
affect BRCA2-dependent HR repair. We
examined the activity of the PALB2 P1
mutant in HR repair using a GFP-based
HR reporter system [20]. In this assay,
we first used PALB2 siRNA to knock
down the endogenous protein and then tested the activities
of exogenous PALB2 proteins expressed from siRNA-resistant
cDNA constructs. As expected, the downregulation of PALB2
by siRNA suppressed HR repair, and reintroduction of wild-
type PALB2 rescued the defect (Figure 4C). In contrast, the
P1 mutant defective in BRCA1 binding failed to rescue HR defi-
ciency, indicating that the interaction between BRCA1 and
PALB2 governs BRCA2-mediated HR repair.
Taken together, our results have demonstrated that (1)
PALB2, a functional partner of BRCA2, directly associates
with BRCA1; (2) PALB2 is the linker between BRCA1 and
BRCA2; (3) BRCA1 promotes the accumulation of PALB2
and BRCA2 at DNA-damage sites; and (4) the interaction
between BRCA1 and PALB2 is critical for HR repair.
BRCA1 and BRCA2 are two important breast tumor
suppressors. Previous results from other groups indicate
that these two tumor suppressors coexist in the same complex
[10, 11]. Here, we found that PALB2 is the bridge that links
BRCA1 and BRCA2. Whereas the C-terminal WD-40 repeats
of PALB2 associates with N-terminus of BRCA2 [3, 8], the
N-terminal coiled-coil motif of PALB2 interacts with the coiled-
coil motif of BRCA1 (Figure S3). Moreover, this BRCA1/PALB2/
BRCA2 complex appears to be important for HR repair after
DNA double-strand breaks. Thus, the functional partnership
between BRCA1 and BRCA2 in the DNA-damage response
may help explain the genetic similarity between these two
breast tumor suppression genes.
BRCA1, PALB2, and BRCA2 not only are breast tumor
suppressors but also play important roles in Fanconi anemia
(FA) [23], a recessive genetic disorder with substantial chro-
mosomal instability. By genetic analysis and complementation
studies, 13 FA proteins have been identified, including PALB2
Current Biology Vol 19 No 6
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identified as FANCN [8, 9]. Although no mutation of BRCA1 has
been found in Fanconi anemia, a BRCA1 BRCT domain partner
BACH1/BRIP1 is FANCJ [24–27]. Like PALB2, BRCA2, and
BRCA1, BACH1/BRIP1 has been shown to participate in
homologous recombination [25]. Moreover, BACH1/BRIP1
also associates with BRCA2 [28]. Thus, it is likely that
BACH1/BRIP1 is another major player in the BRCA1/BRCA2
complex. Given that BACH1/BRIP1 is a DNA helicase [29], it
may unwind the double-strand DNA at damage sites, which
may cooperate with RAD51-dependent homologous pairing
between sister chromatids. Collectively, the physical and func-
tional interactions between BACH1/BRIP1, BRCA1, PALB2,
and BRCA2 may also help explain the genetic links among
these FA genes.
Supplemental Data
Supplemental Data include Supplemental Results, Supplemental Experi-
mental Procedures, and four figures and can be found with this article online
at http://www.current-biology.com/supplemental/S0960-9822(09)00723-4.
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Figure 4. The Interaction between BRCA1 and
PALB2 Is Critical for DNA-Damage-Induced
Focus Formation of BRCA2 and HR Repair
(A) The N-terminal coiled-coil domain of PALB2
interacts with BRCA1. SBP-tagged mutant
PALB2 was expressed in 293T cells. Cell lysates
were analyzed by IP with BRCA1 antibody and
western blotting with FLAG antibody. The
expression level of exogenous PALB2 proteins
was examined by western blotting with FLAG
antibody. The schematic diagrams of PALB2
and its mutants were presented.
(B) The N-terminal domain of PALB2 is essential
for its translocation to DNA-damage sites. Wild-
type PALB2 and the P1, P2, and P13 mutants
were expressed in HeLa cells. Cells were treated
with 10 Gy of IR and stained with indicated anti-
bodies. Foci-positive cells were enumerated.
(C) The N-terminal domain of PALB2 is important
for HR repair. HR assay was performed as ex-
plained inSupplementalExperimentalProcedures.
The error bars were calculated from three indepen-
dent experiments. Exogenous and endogenous
PALB2 were analyzed by indicated antibodies.
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